Novel agents for muscle-invasive and advanced urothelial cancer.

Abstract

Conventional front-line platinum-based combination chemotherapy yields high response rates but suboptimal long-term outcomes for advanced urothelial cancer. Salvage therapy is an unmet need, with disappointing outcomes. The profusion of novel biological agents offers the promise of improved outcomes. Neoadjuvant therapy before cystectomy for muscle-invasive bladder cancer provides an important paradigm and an interesting approach in developing novel agents. Patients who are not candidates for cisplatin require special attention. A multidisciplinary approach and collaboration among laboratory scientists, oncologists, urologists and radiation oncologists is necessary to make therapeutic advances. Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed.

• Authors: Guru Sonpavde, Robert Ross, Thomas Powles, Christopher J Sweeney, Noah Hahn, Thomas E Hutson, Matthew D Galsky, Seth P Lerner, Cora N Sternberg
• Journal: BJU international (BJU Int) Vol. 101 Issue 8 Pg. 937-43 (Apr 2008) ISSN: 1464-410X [Electronic] England
• PMID: 18005203 (Publication Type: Journal Article, Review)

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Transitional Cell (drug therapy, secondary)
• Clinical Trials as Topic
• Humans
• Neoplasm Invasiveness
• Neoplasm Metastasis (drug therapy)
• Treatment Outcome
• Urologic Neoplasms (drug therapy, pathology)